UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 14A

          Consent Statement Pursuant to Section 14(a) of the Securities
                    and Exchange Act of 1934 (Amendment No. )


Filed by the Registrant [  ]

Filed by a Party other than the Registrant [X]

Check the appropriate box:

[ ]  Preliminary Proxy Statement

[ ]  Confidential, for Use of the Commission Only (as permitted by Rule
     14a-6(e)(2))

[ ]  Definitive Proxy Statement

[X]  Definitive Additional Materials

[ ]  Soliciting Material Pursuant to sec. 240.14a-12

                                 NEOPHARM, INC.
                (Name of Registrant as Specified in its Charter)
                              JOHN N. KAPOOR, Ph.D.
   (Name of Person(s) Filing Consent Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]  No fee required.

[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and 0-11

(1)  Title of each class of securities to which transaction applies:

(2)  Aggregate number of securities to which transaction applies:

(3)  Per unit price or other underlying value of transaction computed pursuant
     to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is
     calculated and state how it was determined):

(4)  Proposed maximum aggregate value of transaction:

(5)  Total fee paid:

[ ]  Fee paid previously with preliminary materials.

[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.

(1)  Amount Previously Paid:

(2)  Form, Schedule or Registration Statement No.:

(3)  Filing Party:

(4)  Date Filed:




FOR IMMEDIATE RELEASE


            ISS RECOMMENDS NEOPHARM, INC. (NASDAQ:NEOL) STOCKHOLDERS
                 REMOVE OTHER INCUMBENT DIRECTORS AND RECOMMENDS
                           ELECTION OF KAPOOR NOMINEES


LAKE FOREST, IL - October 18, 2004 -John N. Kapoor, Ph.D. today announced that a
recently released proxy analysis by Institutional Shareholder Services ("ISS"),
the nation's leading independent proxy advisory firm, recommended that clients
holding NeoPharm, Inc. ("NeoPharm") shares support his efforts and consent to
removing incumbent directors Erick E. Hanson, Sander A. Flaum, Dr. Matthew P.
Rogan and Dr. Kaveh T. Safavi (the "Other Incumbent Directors") from NeoPharm's
board of directors and replacing them with Dr. Kapoor's nominees, Mr. Brian
Tambi, Mr. Ronald Eidell and Dr. Bernard A. Fox (the "Nominees"). ISS also
recommended in favor of the other proposals set forth in Dr. Kapoor's consent
solicitation.

The recommendations of ISS are relied upon by hundreds of major institutional
investment firms, mutual funds and other fiduciaries throughout the country. In
conducting its analysis and reaching its recommendations ISS held extensive
discussions with the Other Incumbent Directors, Dr. Kapoor, the Nominees and
NeoPharm's CEO, Greg Young, and CFO, Larry Kenyon.

Dr. Kapoor is one of the founders and a director of NeoPharm and, together with
his wife, its largest stockholder. Dr. Kapoor was quoted as saying: "I am
extremely pleased to have the endorsement of ISS. ISS is a truly independent,
objective, and highly respected, third-party advisory firm and its analysis and
recommendation to NeoPharm holders are well-reasoned and compelling. It is clear
from the ISS report that I am not the only one who is fed up with the `do
nothing' style of the Other Incumbent Directors." In its report ISS said, "the
contribution of the four incumbent board members has been minimal and as a
board, they have failed to provide guidance and supervision to management on
critical issues..."

Dr. Kapoor also indicated that he was happy to see ISS's reaction to his plan to
reduce the cash burn rate of NeoPharm. In its report ISS said "we were
positively impressed with the level of detail behind [Dr. Kapoor's] estimates"
and, in another section of the report it said "[w]e would have preferred to see
the same sense of urgency from the incumbent board, which has not yet discussed
in detail the plan which resulted in the recent press release on the expected
2005 loss."

Dr. Kapoor also stated, "stockholders should also be aware and understand that
ISS did not and you should not buy into the allegations, misinformation and spin
of the Other Incumbent Directors regarding my plans and objectives for your
company and their suggestions that if I am successful in my consent solicitation
the result will be disruption of management and critical clinical trials." The
ISS report stated: "We believe that Mr. Kapoor's significant ownership in
NeoPharm aligns his interests with shareholders and that a change in board
control at this stage would not threaten progress on IL-13."

With respect to the disruption issue, Dr. Kapoor continued by saying: "This is a
very professional and capable management group. I have worked closely with most
of them for years and I look forward to working with the new CEO, Greg Young,
and continuing to work with this



management team under Greg's direction to get NeoPharm back on track." Dr.
Kapoor also noted: "The management and employees of NeoPharm, like other
stockholders, have lost tremendous value during the catastrophic drop in stock
price this year and for many of them their stock options are under water. My
interest is also firmly aligned with theirs in setting NeoPharm on a sustainable
course for the future."

Dr. Kapoor continued: "I did not commence this solicitation in order to keep
Greg Young from having time to develop and implement a plan as the Other
Incumbent Directors have suggested. Rather, I commenced this solicitation in
order to ensure that there would be a viable and realistic plan to implement.
The Other Incumbent Directors have no plan and are not interested in developing
one. They were never interested in my plans and they have shown little or no
interest in having management develop a plan. Their attitude is the same as
always: do nothing. An active and engaged Board does not mean disruption. It
means good governance and a bright future for NeoPharm."

Dr. Kapoor concluded by saying, "I believe that ISS correctly found that the
true issue in this consent solicitation is: `Who is more likely to restore and
enhance value for NeoPharm stockholders in the future?' ISS's answer: the
Nominees and myself. Together, we will work actively with management to
implement the reforms that NeoPharm so desperately needs. I urge NeoPharm
stockholders to sign, date and return the WHITE consent card today, consenting
to the election of the Nominees and removing the Other Incumbent Directors from
NeoPharm's board."

For more information about how to execute and deliver your consent, or if you
have any questions or require any assistance, please contact our consent
solicitor, Innisfree M&A Incorporated, toll-free at 1-888-750-5834.

Source:  EJ Financial Enterprises, Inc.
         Michael L. Babich (847) 296-8665 ext. 120